Platinum(II) Complexes with O,S Bidentate Ligands: Biophysical Characterization, Antiproliferative Activity, and Crystallographic Evidence of Protein Binding.

We recently characterized a series of novel platinum(II) compounds bearing a conserved O,S binding moiety as a bifunctional ligand and evaluated their solution behavior and antiproliferative properties in vitro against a representative cancer cell line. On the whole, those platinum compounds showed an appreciable stability in mixed dimethyl sulfoxide-aqueous buffers and promising in vitro cytotoxic effects; yet they manifested a rather limited solubility in aqueous media making them poorly suitable for further pharmaceutical development. To overcome this drawback, four new derivatives of this series were prepared and characterized based on a careful choice of substituents on the O,S bidentate ligand. The solubility and stability profile of these novel compounds in a reference buffer was determined, as well as the ligands' log P(o/w) value (P(o/w) = n-octanol-water partition coefficient) as an indirect measure for the complexes' lipophilicity. The antiproliferative properties were comparatively evaluated in a panel of three cancer cell lines. The protein binding properties of the four platinum compounds were assessed using the model protein hen egg white lysozyme (HEWL), and the molecular structures of two relevant HEWL-metallodrug adducts were solved. Overall, it is shown that a proper choice of the substituents leads to a higher solubility and enables a selective fine-tuning of the antiproliferative properties. The implications of these results are thoroughly discussed.

[1]  A. Merlino,et al.  The X-ray structure of the complex formed in the reaction between oxaliplatin and lysozyme. , 2014, Chemical communications.

[2]  N. Metzler‐Nolte,et al.  Biologically Active Trifluoromethyl-Substituted Metallocene Triazoles: Characterization, Electrochemistry, Lipophilicity, and Cytotoxicity , 2012 .

[3]  James L. Hickey,et al.  Cationic, linear Au(I) N-heterocyclic carbene complexes: synthesis, structure and anti-mitochondrial activity. , 2006, Dalton transactions.

[4]  Domenico Osella,et al.  The RP-HPLC measurement and QSPR analysis of logP(o/w) values of several Pt(II) complexes. , 2006, Journal of inorganic biochemistry.

[5]  Dong Wang,et al.  Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.

[6]  A. Merlino,et al.  Interactions of gold-based drugs with proteins: the structure and stability of the adduct formed in the reaction between lysozyme and the cytotoxic gold(III) compound Auoxo3. , 2014, Dalton transactions.

[7]  P. Tchounwou,et al.  Cisplatin in cancer therapy: molecular mechanisms of action. , 2014, European journal of pharmacology.

[8]  K. Diederichs,et al.  Carboplatin binding to histidine , 2014, Acta crystallographica. Section F, Structural biology communications.

[9]  N. Pannu,et al.  REFMAC5 for the refinement of macromolecular crystal structures , 2011, Acta crystallographica. Section D, Biological crystallography.

[10]  M. Dolan,et al.  Molecular mechanisms of resistance and toxicity associated with platinating agents. , 2007, Cancer treatment reviews.

[11]  A. Vergara,et al.  Investigating the ruthenium metalation of proteins: X-ray structure and Raman microspectroscopy of the complex between RNase A and AziRu. , 2013, Inorganic chemistry.

[12]  H. Görls,et al.  Novel platinum(II) compounds with O,S bidentate ligands: synthesis, characterization, antiproliferative properties and biomolecular interactions. , 2014, Dalton transactions.

[13]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[14]  G. Natile,et al.  Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA , 2009 .

[15]  Reactions of cytotoxic metallodrugs with lysozyme in pure DMSO explored through UV–Vis absorption spectroscopy and ESI MS , 2015, BioMetals.

[16]  G. Natile,et al.  An Updated View of Cisplatin Transport , 2013 .

[17]  B. Spingler,et al.  Tricarbonylmanganese(I) and –rhenium(I) Complexes of Imidazol‐Based Phosphane Ligands: Influence of the Substitution Pattern on the CO Release Properties , 2009 .

[18]  A. Merlino,et al.  Peculiar features in the crystal structure of the adduct formed between cis-PtI2(NH3)2 and hen egg white lysozyme. , 2013, Inorganic chemistry.

[19]  Jan Reedijk,et al.  Interactions of anticancer Pt compounds with proteins: an overlooked topic in medicinal inorganic chemistry? , 2012 .

[20]  Michael Groessl,et al.  Anticancer metallodrug research analytically painting the “omics” picture—current developments and future trends , 2013, Analytical and Bioanalytical Chemistry.

[21]  W. Berger,et al.  In vitro studies on cisplatin focusing on kinetic aspects of intracellular chemistry by LC-ICP-MS. , 2013, Metallomics : integrated biometal science.

[22]  Rita Grandori,et al.  Testing the role of solvent surface tension in protein ionization by electrospray. , 2005, Journal of mass spectrometry : JMS.

[23]  C. Supuran,et al.  ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme. , 2007, Chemical communications.

[24]  T. Hambley,et al.  Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs , 2000, British Journal of Cancer.

[25]  A. Merlino,et al.  Oxaliplatin vs. cisplatin: competition experiments on their binding to lysozyme. , 2015, Dalton transactions.

[26]  R. Silaghi-Dumitrescu,et al.  Interactions between proteins and platinum-containing anti-cancer drugs. , 2011, Mini reviews in medicinal chemistry.

[27]  A. Merlino,et al.  Interactions between anticancer trans-platinum compounds and proteins: crystal structures and ESI-MS spectra of two protein adducts of trans-(dimethylamino)(methylamino)dichloridoplatinum(II). , 2014, Inorganic chemistry.

[28]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[29]  A. Berthod,et al.  Determination of liquid-liquid partition coefficients by separation methods. , 2004, Journal of chromatography. A.

[30]  H. Görls,et al.  Synthese und Charakterisierung funktionalisierter β‐Hydroxydithiozimtsäuren und deren Ester. Komplexchemisches Verhalten gegenüber Nickel(II), Palladium(II) und Platin(II) , 2006 .

[31]  D. F. Koenig,et al.  Structure of Hen Egg-White Lysozyme: A Three-dimensional Fourier Synthesis at 2 Å Resolution , 1965, Nature.

[32]  A. Merlino,et al.  Protein Recognition of Gold-Based Drugs: 3D Structure of the Complex Formed When Lysozyme Reacts with Aubipy(c.). , 2014, ACS medicinal chemistry letters.

[33]  A. Merlino,et al.  Ruthenium metalation of proteins: the X-ray structure of the complex formed between NAMI-A and hen egg white lysozyme. , 2014, Dalton transactions.

[34]  J. Helliwell,et al.  The crystal structure analysis of the relative binding of cisplatin and carboplatin in a mixture with histidine in a protein studied at 100 and 300 K with repeated X-ray irradiation. , 2013, Acta crystallographica. Section D, Biological crystallography.

[35]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[36]  M. A. Patrick,et al.  A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography. , 1988, Journal of medicinal chemistry.

[37]  N. Farrell,et al.  Platinum-based drugs and proteins: reactivity and relevance to DNA adduct formation. , 2013, Journal of inorganic biochemistry.

[38]  M. Palacios,et al.  Analytical methodologies for metallomics studies of antitumor Pt-containing drugs. , 2010, Metallomics : integrated biometal science.

[39]  J. Helliwell,et al.  Structural studies of the effect that dimethyl sulfoxide (DMSO) has on cisplatin and carboplatin binding to histidine in a protein. , 2012, Acta crystallographica. Section D, Biological crystallography.

[40]  A. Vergara,et al.  The mode of action of anticancer gold-based drugs: a structural perspective. , 2013, Chemical communications.